Scarica l'app Stockscreener
1.31
3.15%
0.04
Dopo l'orario di chiusura:
1.27
-0.04
-3.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.27
Aprire:
$1.27
Volume 24 ore:
297.33K
Relative Volume:
0.67
Capitalizzazione di mercato:
$85.81M
Reddito:
-
Utile/perdita netta:
$-30.04M
Rapporto P/E:
-0.8291
EPS:
-1.58
Flusso di cassa netto:
$-27.38M
1 W Prestazione:
+8.26%
1M Prestazione:
+3.97%
6M Prestazione:
-20.61%
1 anno Prestazione:
-13.25%
Intervallo 1D:
$1.27
$1.39
Intervallo di 1 settimana:
$1.20
$1.39
Portata 52W:
$0.8301
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Nome
Regulus Therapeutics Inc
Settore
Industria
Telefono
858-202-6300
Indirizzo
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Confronta RGLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.31 | 85.81M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-03-18 | Iniziato | Leerink Partners | Outperform |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Iniziato | Leerink Partners | Outperform |
| 2017-06-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-06 | Reiterato | Wedbush | Outperform |
| 2017-01-30 | Downgrade | Needham | Buy → Hold |
| 2017-01-30 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-11-02 | Reiterato | Needham | Buy |
| 2016-07-25 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | FBR Capital | Outperform |
| 2016-06-28 | Reiterato | Needham | Buy |
| 2016-06-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-04-13 | Iniziato | Chardan Capital Markets | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2015-04-21 | Ripresa | FBR Capital | Outperform |
| 2014-11-24 | Iniziato | Deutsche Bank | Buy |
| 2014-08-07 | Reiterato | FBR Capital | Outperform |
| 2013-08-14 | Reiterato | Needham | Buy |
Mostra tutto
Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily
Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel
RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar
Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat
Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat
JPMorgan Chase & Co. Raises Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Insider Moves Spark Interest: Is Regulus Therapeutics Set for a Comeback? - Jomfruland.net
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance
CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares - Simply Wall St
Insider Buying: David Baltimore Acquires Shares of Regulus Thera - GuruFocus.com
Insider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus T - GuruFocus.com
Regulus stock tumbles 24% amid study, regulatory updates - MSN
REVB Start 1B Trial and Announces Split - MSN
Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Tria - GuruFocus.com
Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data - Yahoo Finance
Regulus Therapeutics Kidney Disease Treatment Shows Response in Early-stage Trial -- Shares Fall - Marketscreener.com
Regulus stock tumbles 24% amid study, regulatory updates (RGLS:NASDAQ) - Seeking Alpha
Regulus reports progress in ADPKD trial and FDA talks - MSN
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) - Citizentribune
Regulus Therapeutics (RGLS) Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen - StreetInsider.com
Regulus Therapeutics stock hits 52-week low at $1.16 - MSN
Regulus Therapeutics stock hits 52-week low at $1.16 By Investing.com - Investing.com South Africa
Barclays PLC Grows Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics CFO sells shares worth $55,333 By Investing.com - Investing.com South Africa
Jane Street Group LLC Takes $46,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics president sells $39,721 in stock By Investing.com - Investing.com Australia
Regulus Therapeutics CEO sells shares worth $160,494 By Investing.com - Investing.com Canada
Regulus therapeutics executive sells shares worth $55,119 By Investing.com - Investing.com Nigeria
Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of Stock - MarketBeat
Joseph P. Hagan Sells 115,290 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock - MarketBeat
Christopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada Sells 38,716 Shares - MarketBeat
Regulus therapeutics executive sells shares worth $55,119 - Investing.com India
Regulus Therapeutics president sells $39,721 in stock - Investing.com
Regulus Therapeutics CFO sells shares worth $55,333 - Investing.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Consensus PT from Analysts - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by State Street Corp - Defense World
This Biotech Wasted No Time Stealing The Premarket Show - MSN
Regulus Therapeutics Announces Completion of Enrollment in Secon - GuruFocus.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Target Price from Analysts - Defense World
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - The Eastern Progress Online
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
Regulus Therapeutics Inc Azioni (RGLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regulus Therapeutics Inc Azioni (RGLS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BALTIMORE DAVID | Director |
Jan 30 '25 |
Buy |
1.06 |
19,610 |
20,787 |
22,169 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 13 '25 |
Sale |
1.26 |
38,547 |
48,693 |
54,634 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
49,546 |
| Hagan Joseph P | Chief Executive Officer |
Jan 13 '25 |
Sale |
1.26 |
115,290 |
145,634 |
222,572 |
| Hagan Joseph P | Chief Executive Officer |
Jan 14 '25 |
Sale |
1.26 |
11,764 |
14,860 |
210,808 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 13 '25 |
Sale |
1.26 |
38,716 |
48,906 |
50,566 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
45,478 |
| Klassen Preston | President & Head of R & D |
Jan 13 '25 |
Sale |
1.26 |
31,445 |
39,721 |
36,055 |
| Collier Kathryn J | Director |
Jul 25 '24 |
Buy |
1.82 |
4,000 |
7,280 |
6,740 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):